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Diabetes and osteoporosis are both frequent disorders. By chance
they may thus occur together. However, evidence suggests that
osteoporosis defined by bone scans (DXA) occurs more frequent
than expected in type 1 diabetes (T1D) and less frequent than
expected in T2D (1). The latter may be explained by differ-
ences in body size – T2D patients being more obese than the
general population and bone mineral density (BMD) increases
with body size (2). However, as disclosed by prior studies and
by the papers in this research topic, more is present than what
meets the eye at first glance on the bone density measures. More
fractures are present than expected both in T1D and T2D. This
could point at either a diminished bone biomechanical com-
petence or an increased risk of trauma. The latter seems less
likely. Regarding bone biomechanical competence, this series of
papers has shown discordances in biochemical markers of bone
turnover (3). This raises the question of the potential mechanisms
of uncoupling of formation and resorption, and thus a poten-
tial weakening of bone microarchitecture. Besides the issue of the
interactions with bone cells such as the osteoclasts, osteocytes,
and osteoblasts, interactions with both the calcium matrix and
thus the crystalline structure of hydroxyapatite and interactions
with collagen are possible. This opens for a wide range of pos-
sible research fields within signaling [bone – adipose tissue (4),
bone – pancreas etc.], imaging (crystal structure), engineering
(biomechanical properties) etc.
Within each of these fields, a number of questions need to be
addressed. Are the measurements of biochemical markers of bone
turnover reliable? One example could be if enzymatic or non-
enzymatic modification of say collagen cross-links could infer
with the accuracy of assays, thus measuring lower concentra-
tions as not all of the degraded collagen is detected. Furthermore,
many interactions between glucose and osteocalcin (5) modify the
effectiveness of this as a marker of bone turnover.
The change in biochemical markers happen rather rapidly and
were in one study modified by somatostatin. The rapid changes
raise novel questions as bone turnover usually is a rather slow
process that takes more than hours to modify substantially. How-
ever, the interaction with somatostatin raises the possibility of
an interaction from gut hormones (6) and ghrelin. Studies of a
broader range of hormonal signaling may thus be in place.
The field of biomechanical competence may call for novel imag-
ining techniques and new methods to study crystal structure and
biomechanical competence.
The study of diabetes and bone thus not only relates to clas-
sical endocrinology and bone metabolism, but also opens new
concepts of bone biomechanical competence beyond traditional
DXA techniques and even beyond HrpQCT and beyond classical
biochemical markers of bone turnover.
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